Clinical Trial Biorepository & Archiving Solutions Market Size to Hit US$ 10.1 Bn by 2030

The Clinical Trial Biorepository & Archiving Solutions market size is expected to hit around US$ 10.1 billion by 2030 and is anticipated to grow at a CAGR of 15.2% during forecast period 2021 to 2030.

Growth Factors

This is largely due to the increasing importance of biological sample management in and the desire to streamline the collection and reporting of data. Biorepositories have entered the Big Data era, which requires new IT technologies, artificial intelligence (AI) techniques, and deep learning tools and algorithms. These features help to the paradigm shift toward data-driven science by higher-quality biobanking data. Cloud storage and other new data storage technologies help to solve the problem of limited local storage capacity.

Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38472

New IT solutions such as the sample/data negotiator and locator, which are part of the BBMRI-ERIC infrastructure, make it easier to discover samples and data that meet specific criteria. This new level of biobanking activity contributes to basic research, translational research, and therapy of a wide range of human disorders, including cancer, CVD rare diseases, diabetes, and neurodegenerative diseases.

Report Highlights

Biorepository services led the market and accounted for 87.2% share in 2020. Stringent regulations such as Health Insurance Portability and Accountability Act (HIPAA), Right to Withdraw, European Union General Data Protection Regulation, and other regulations regarding sample custody and ownership, human tissues and informed consent, and access to biospecimens are anticipated to improve data protection and patient privacy.

The phase III clinical trials segment held the largest share of 62.1% in 2020. Phase III clinical trials investigators compare the new treatment’s safety and effectiveness against the current standard of care. A substantial number of patients, at least several hundred, participate in most phase III clinical trials.

The clinical products segment led the market and accounted for 73.1% share in 2020. The segment is anticipated to register the fastest growth rate throughout the forecast period. This is due to an increase in the number of clinical trial registrations in recent years.

The preclinical products segment is anticipated to witness substantial growth over the forecast period. An increasing number of molecules in the preclinical stage is anticipated to create significant opportunities for market players.

North America led the market with a share of 59.7% in 2020. The region is also expected to grow at a significant rate during the forecast period. The rise in the number of clinical trials, the presence of a large number of players in the market, and the availability of modern technology are among the primary factors driving this regional market.

Key Players

• Brooks Life Science
• Patheon
• Precision for Medicine, Inc.
• Medpace
• LabCorp Drug Development
• ATCC
• Q2 Solutions
• Labconnect
• Charles River Laboratories
• Cell&Co

Market Segmentation

• Service
  • Biorepository Services
    • Warehousing & Storage
    • Transportation
    • Sample Processing
    • Others
  • Archiving Solution Services
    • Database Indexing and Management
    • Scanning & Destruction
• Product
  • Preclinical Products
  • Clinical Products
    • Human Tissue
    • Organs
    • Stem Cells
    • Other Biospecimens
• Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• Regional
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38472

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333